MAPT and Alzheimer disease: We therefore conducted sensitivity analyses by performing MGWAS including either only healthy (N = 883) or AD individuals (N = 769) based on the biomarker status (amyloid/tau/neurodegeneration (ATN) classification (see extended results)).